221 related articles for article (PubMed ID: 31060912)
1. B7-H3 and its role in bone cancers.
He L; Li Z
Pathol Res Pract; 2019 Jun; 215(6):152420. PubMed ID: 31060912
[TBL] [Abstract][Full Text] [Related]
2. Targeting osteosarcoma with canine B7-H3 CAR T cells and impact of CXCR2 Co-expression on functional activity.
Cao JW; Lake J; Impastato R; Chow L; Perez L; Chubb L; Kurihara J; Verneris MR; Dow S
Cancer Immunol Immunother; 2024 Mar; 73(5):77. PubMed ID: 38554158
[TBL] [Abstract][Full Text] [Related]
3. B7-H3 is overexpressed in patients suffering osteosarcoma and associated with tumor aggressiveness and metastasis.
Wang L; Zhang Q; Chen W; Shan B; Ding Y; Zhang G; Cao N; Liu L; Zhang Y
PLoS One; 2013; 8(8):e70689. PubMed ID: 23940627
[TBL] [Abstract][Full Text] [Related]
4. Molecular Pathways: Targeting B7-H3 (CD276) for Human Cancer Immunotherapy.
Picarda E; Ohaegbulam KC; Zang X
Clin Cancer Res; 2016 Jul; 22(14):3425-3431. PubMed ID: 27208063
[TBL] [Abstract][Full Text] [Related]
5. B7-H3-targeted CAR-T cell therapy for solid tumors.
Li G; Wang H; Wu H; Chen J
Int Rev Immunol; 2022; 41(6):625-637. PubMed ID: 35855615
[TBL] [Abstract][Full Text] [Related]
6. A high-content screen of FDA approved drugs to enhance CAR T cell function: ingenol-3-angelate improves B7-H3-CAR T cell activity by upregulating B7-H3 on the target cell surface via PKCĪ± activation.
Lee HW; O'Reilly C; Beckett AN; Currier DG; Chen T; DeRenzo C
J Exp Clin Cancer Res; 2024 Apr; 43(1):97. PubMed ID: 38561833
[TBL] [Abstract][Full Text] [Related]
7. B7-H3 in Brain Malignancies: Immunology and Immunotherapy.
Guo X; Chang M; Wang Y; Xing B; Ma W
Int J Biol Sci; 2023; 19(12):3762-3780. PubMed ID: 37564196
[TBL] [Abstract][Full Text] [Related]
8. B7-H3, a checkpoint molecule, as a target for cancer immunotherapy.
Yang S; Wei W; Zhao Q
Int J Biol Sci; 2020; 16(11):1767-1773. PubMed ID: 32398947
[TBL] [Abstract][Full Text] [Related]
9. Switchable CAR T cell strategy against osteosarcoma.
Hidalgo L; Somovilla-Crespo B; Garcia-Rodriguez P; Morales-Molina A; Rodriguez-Milla MA; Garcia-Castro J
Cancer Immunol Immunother; 2023 Aug; 72(8):2623-2633. PubMed ID: 37062034
[TBL] [Abstract][Full Text] [Related]
10. B7-H3/CD276: An Emerging Cancer Immunotherapy.
Zhou WT; Jin WL
Front Immunol; 2021; 12():701006. PubMed ID: 34349762
[TBL] [Abstract][Full Text] [Related]
11. A Novel Orthotopic Implantation Technique for Osteosarcoma Produces Spontaneous Metastases and Illustrates Dose-Dependent Efficacy of B7-H3-CAR T Cells.
Talbot LJ; Chabot A; Funk A; Nguyen P; Wagner J; Ross A; Tillman H; Davidoff A; Gottschalk S; DeRenzo C
Front Immunol; 2021; 12():691741. PubMed ID: 34211478
[TBL] [Abstract][Full Text] [Related]
12. Targeting B7-H3-A Novel Strategy for the Design of Anticancer Agents for Extracranial Pediatric Solid Tumors Treatment.
Rasic P; Jeremic M; Jeremic R; Dusanovic Pjevic M; Rasic M; Djuricic SM; Milickovic M; Vukadin M; Mijovic T; Savic D
Molecules; 2023 Apr; 28(8):. PubMed ID: 37110590
[TBL] [Abstract][Full Text] [Related]
13. B7-H3 targeted CAR-T cells show highly efficient anti-tumor function against osteosarcoma both in vitro and in vivo.
Zhang Q; Zhang Z; Liu G; Li D; Gu Z; Zhang L; Pan Y; Cui X; Wang L; Liu G; Tian X; Zhang Z
BMC Cancer; 2022 Nov; 22(1):1124. PubMed ID: 36320072
[TBL] [Abstract][Full Text] [Related]
14. Expression of B7-H3 in cancer tissue during osteosarcoma progression in nude mice.
Yin SJ; Wang WJ; Zhang JY
Genet Mol Res; 2015 Nov; 14(4):14253-61. PubMed ID: 26600483
[TBL] [Abstract][Full Text] [Related]
15. B7-H3 Negatively Modulates CTL-Mediated Cancer Immunity.
Yonesaka K; Haratani K; Takamura S; Sakai H; Kato R; Takegawa N; Takahama T; Tanaka K; Hayashi H; Takeda M; Kato S; Maenishi O; Sakai K; Chiba Y; Okabe T; Kudo K; Hasegawa Y; Kaneda H; Yamato M; Hirotani K; Miyazawa M; Nishio K; Nakagawa K
Clin Cancer Res; 2018 Jun; 24(11):2653-2664. PubMed ID: 29530936
[No Abstract] [Full Text] [Related]
16. Targeting Radiation-Resistant Prostate Cancer Stem Cells by B7-H3 CAR T Cells.
Zhang Y; He L; Sadagopan A; Ma T; Dotti G; Wang Y; Zheng H; Gao X; Wang D; DeLeo AB; Fan S; Sun R; Yu L; Zhang L; Wang G; Ferrone S; Wang X
Mol Cancer Ther; 2021 Mar; 20(3):577-588. PubMed ID: 33653946
[TBL] [Abstract][Full Text] [Related]
17. Immune checkpoint of B7-H3 in cancer: from immunology to clinical immunotherapy.
Zhao B; Li H; Xia Y; Wang Y; Wang Y; Shi Y; Xing H; Qu T; Wang Y; Ma W
J Hematol Oncol; 2022 Oct; 15(1):153. PubMed ID: 36284349
[TBL] [Abstract][Full Text] [Related]
18. The role of B7-H3 in tumors and its potential in clinical application.
Feng R; Chen Y; Liu Y; Zhou Q; Zhang W
Int Immunopharmacol; 2021 Dec; 101(Pt B):108153. PubMed ID: 34678689
[TBL] [Abstract][Full Text] [Related]
19. B7-H3 as a promising target for cytotoxicity T cell in human cancer therapy.
Ma J; Ma P; Zhao C; Xue X; Han H; Liu C; Tao H; Xiu W; Cai J; Zhang M
Oncotarget; 2016 May; 7(20):29480-91. PubMed ID: 27121051
[TBL] [Abstract][Full Text] [Related]
20. The tumor suppressor miR-124 inhibits cell proliferation and invasion by targeting B7-H3 in osteosarcoma.
Wang L; Kang FB; Sun N; Wang J; Chen W; Li D; Shan BE
Tumour Biol; 2016 Nov; 37(11):14939-14947. PubMed ID: 27644254
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]